De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

References

• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045–1057. doi: 10.1056/NEJMoa0904327.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39(3):213–260. doi: 10.1093/eurheartj/ehw180.
   PubMed Web of Science ®Google Scholar
• Floyd CN, Passacquale G, Ferro A. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet 2012;51(7):429–442. doi:10.2165/11630740-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008;51(21):2028–2033. doi:10.1016/j.jacc.2008.04.002.
   PubMed Web of Science ®Google Scholar
• Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32(23):2933–2944. doi: 10.1093/eurheartj/ehr422.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017;38(41):3070–3078. doi: 10.1093/eurheartj/ehx175.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017;390(10104):1747–1757. doi: 10.1016/S0140-6736(17)32155-4.
   PubMed Web of Science ®Google Scholar
• Ueno T, Koiwaya H, Sasaki KI, Katsuki Y, Katsuda Y, Murasato Y, Shimamatsu J, Umeji K, Otsuka Y, Kawasaki T, et al. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting. Cardiovasc Interv Ther 2017;32(4):341–350. doi: 10.1007/s12928-016-0417-x.
   PubMed Web of Science ®Google Scholar
• Biscaglia S, Campo G, Pavasini R, Tebaldi M, Tumscitz C, Ferrari R. Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets 2016;27(5):484–487. doi:10.3109/09537104.2015.1119815.
   PubMed Web of Science ®Google Scholar
• Kudaravalli M, Althouse AD, Marroquin OC, Khandhar SJ, Sharbaugh MS, Toma C, Conrad Smith AJ, Schindler JT, Lee JS, Mulukutla SR. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization. Int J Cardiol 2016;223:854–859. doi: 10.1016/j.ijcard.2016.08.144.
   PubMed Web of Science ®Google Scholar
• Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, Cheema AN, Peterson ED, Saucedo JF, Granger CB, et al. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv 2014;7(4):585–593. doi: 10.1161/CIRCINTERVENTIONS.114.001555.
   PubMed Web of Science ®Google Scholar
• Bagai A, Peterson ED, Honeycutt E, Effron MB, Cohen DJ, Goodman SG, Anstrom KJ, Gupta A, Messenger JC, Wang TY. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care 2015;4(6):499–508. doi:10.1177/2048872614564082.
   PubMed Web of Science ®Google Scholar
• Zanchin T, Temperli F, Karagiannis A, Zanchin C, Rasanen M, Koskinas KC, Stortecky S, Hunziker L, Praz F, Blochlinger S, et al. Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the bern percutaneous coronary intervention registry. Circ Cardiovasc Interv 2018;11(5):e006132. doi: 10.1161/CIRCINTERVENTIONS.118.006388.
   PubMed Web of Science ®Google Scholar
• Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, Dusek J, Jarkovsky J, Miklik R, Rokyta R, et al. 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol 2018;71(4):371–381. doi: 10.1016/j.jacc.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Wang X, Xi S, Liu J, Qin L, Jing J, Yin T, Chen Y. Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. Eur Heart J Suppl 2016;18(SupplF):F19–F26. doi:10.1093/eurheartj/suw034.
   PubMedGoogle Scholar
• Schiele F, Puymirat E, Bonello L, Meneveau N, Collet JP, Motreff P, Ravan R, Leclercq F, Ennezat PV, Ferrieres J, et al. Switching between thienopyridines in patients with acute myocardial infarction and quality of care. Open Heart 2016;3(1):e000384. doi: 10.1136/openhrt-2015-000384.
   PubMed Web of Science ®Google Scholar
• Hamid T, Zaman M, Rose S, Malik N. Switching of ticagrelor to clopidogrel at 3 months in patients treated for acute care syndrome; single centre experience. Cardiovasc Pharm Open Access 2016;5:194. doi: 10.4172/2329-6607.1000194.
   Google Scholar
• Kerneis M, Silvain J, Abtan J, Cayla G, O’Connor SA, Barthelemy O, Vignalou JB, Beygui F, Brugier D, Martin R, et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv 2013;6(2):158–165. doi: 10.1016/j.jcin.2012.09.012.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494–502. doi:10.1056/NEJMoa010746.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64(24):e139–e228. doi: 10.1016/j.jacc.2014.09.017.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. COMMIT (ClOpidogrel andMetoprolol inMyocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1607–1621. doi:10.1016/S0140-6736(05)67528-9.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91(9):1123–1125.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45(2):246–251. doi:10.1016/j.jacc.2004.09.067.
   PubMed Web of Science ®Google Scholar
• Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57(25):2474–2483. doi:10.1016/j.jacc.2010.12.047.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bainey KR, Cantor WJ, Lordkipanidzé M, Marquis-Gravel G, Robinson SD, Sibbald M, So DY, Wong GC, Abunassar JG, et al. 2018 Canadian Cardiovascular Society (CCS)/Canadian Association of Interventional Cardiology (CAIC) Focused Update of the Guidelines for the use of Antiplatelet Therapy. Can J Cardiol 2018;34(3):214–233. doi: 10.1016/j.cjca.2017.12.012.
   PubMed Web of Science ®Google Scholar
• De Luca L, D’Ascenzo F, Musumeci G, Saia F, Parodi G, Varbella F, Marchese A, De Servi S, Berti S, Bolognese L. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention 2017;13(4):459–466. doi:10.4244/EIJ-D-17-00092.
   PubMed Web of Science ®Google Scholar
• Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, Baker BA, Messenger JC, Cohen DJ, Wang TY, et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: insights from the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) observational study. Am Heart J 2017;183:62–68.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol 2016;1(4):425–432. doi: 10.1001/jamacardio.2016.1017.
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Cho JR, DeGroat C, Bhatti M, Muniz-Lozano A, Singh K, Ferrante E, Wilson RE, Dunn EC, et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J 2016;37(35):2722–2730. doi: 10.1093/eurheartj/ehv744.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017;136(20):1955–1975. doi: 10.1161/CIRCULATIONAHA.117.027612.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas Rios J, Rivas A, Agarwal M, Kureti M, Nagaraju D, Wali M, Shaikh Z, Briceno M, et al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study. Circulation 2018;137(23):2450–2462. doi: 10.1161/CIRCULATIONAHA.118.033983.
   PubMed Web of Science ®Google Scholar